标题
If Small Molecules Immunotherapy Comes, Can the Prime be Far Behind?
作者
关键词
Cancer immunotherapy, Small molecule inhibitors, Combination therapy, Tumor microenvironment
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages 113356
出版商
Elsevier BV
发表日期
2021-03-12
DOI
10.1016/j.ejmech.2021.113356
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Small molecule targeting of SHIP1 and SHIP2
- (2020) William G. Kerr et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs
- (2020) Marco De Dominici et al. BLOOD
- Cellular Immunotherapy in Lymphoma: Beyond CART Cells
- (2020) Mahmoud R. Gaballa et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Zanubrutinib: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Arginase inhibitor, Nω-hydroxy-L-norarginine, spontaneously releases biologically active NO-like molecule: Limitations for research applications
- (2020) Tony Y. Momma et al. FREE RADICAL BIOLOGY AND MEDICINE
- A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies.
- (2020) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer.
- (2020) David R. Wise et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
- (2020) Daixi Ren et al. Molecular Cancer
- Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
- (2020) Niall A. Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tirabrutinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage
- (2020) Hao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
- (2020) Cindy Patinote et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Gasdermin E suppresses tumour growth by activating anti-tumour immunity
- (2020) Zhibin Zhang et al. NATURE
- A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology
- (2020) So Myoung Lee et al. ACS Synthetic Biology
- Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
- (2020) Krista Isaac et al. Cancer Management and Research
- Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
- (2020) Chunyong Ding et al. Acta Pharmaceutica Sinica B
- Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
- (2020) Dimitar G. Efremov et al. Cancers
- The adenosine pathway in immuno-oncology
- (2020) Bertrand Allard et al. Nature Reviews Clinical Oncology
- Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders
- (2020) Kai Tang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
- (2020) Leila Motedayen Aval et al. Journal of Clinical Medicine
- Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
- (2020) Yufei Wang et al. Cancers
- Correction to “Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein”
- (2020) Mingliang Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
- (2019) Daniel Shae et al. Nature Nanotechnology
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
- (2019) Jun Wang et al. NATURE MEDICINE
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors
- (2019) Jeffrey T. Bagdanoff et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
- (2019) Yifan Feng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
- (2019) Mehrdad Mobasher et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling
- (2019) Eunhee Choi et al. Nature Communications
- Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist
- (2019) Xiaohui Zhang et al. ACS Infectious Diseases
- STING pathway agonism as a cancer therapeutic
- (2019) Blake A. Flood et al. IMMUNOLOGICAL REVIEWS
- Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
- (2019) Subhadwip Basu et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROTACs– a game-changing technology
- (2019) Markella Konstantinidou et al. Expert Opinion on Drug Discovery
- TGF-β signaling controls Foxp3 methylation and T reg cell differentiation by modulating Uhrf1 activity
- (2019) Xiang Sun et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
- (2019) Stefanie R. Mullins et al. Journal for ImmunoTherapy of Cancer
- STING Activation and its Application in Immuno-Oncology
- (2019) Yiqian Lian et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research
- (2019) David C. McGowan CURRENT TOPICS IN MEDICINAL CHEMISTRY
- STING: a master regulator in the cancer-immunity cycle
- (2019) Yuanyuan Zhu et al. Molecular Cancer
- The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma
- (2019) Martin K. Thomsen et al. ONCOGENE
- Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
- (2019) Kelsey E. Sivick et al. Cell Reports
- A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
- (2019) Huynh et al. Biomolecules
- Targeting SHP2 as a promising strategy for cancer immunotherapy
- (2019) Qianqian Liu et al. PHARMACOLOGICAL RESEARCH
- The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
- (2019) John Kwon et al. Cancer Discovery
- Dual Allosteric Inhibition of SHP2 Phosphatase
- (2018) Michelle Fodor et al. ACS Chemical Biology
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors
- (2018) Thomas Pleli et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
- (2018) Chengyuan Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma
- (2018) Carmela De Santo et al. Journal of Hematology & Oncology
- Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
- (2018) Karen O. Dixon et al. JOURNAL OF IMMUNOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacology of Adenosine Receptors: The State of the Art
- (2018) Pier Andrea Borea et al. PHYSIOLOGICAL REVIEWS
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
- (2018) Christopher B. Rodell et al. Nature Biomedical Engineering
- Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists
- (2018) David C. McGowan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
- (2018) Abdi Ghaffari et al. BRITISH JOURNAL OF CANCER
- Recent advances in small molecule based cancer immunotherapy
- (2018) Binbin Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Epidermal mast cells in Bowenoid papulosis during topical imiquimod therapy
- (2018) Takako Miura et al. JOURNAL OF DERMATOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
- (2018) Stephen B. Willingham et al. Cancer Immunology Research
- A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily
- (2018) Anil Korkut et al. Cell Systems
- SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
- (2018) Mingxia Zhao et al. Acta Pharmaceutica Sinica B
- Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial
- (2018) M R Gaiser et al. ANNALS OF ONCOLOGY
- Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
- (2018) Tingkai Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
- (2018) Lisa Seitz et al. INVESTIGATIONAL NEW DRUGS
- The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
- (2018) William G. Kerr et al. JOURNAL OF IMMUNOLOGY
- Recent clinical trends in Toll-like receptor targeting therapeutics
- (2018) Muhammad Ayaz Anwar et al. MEDICINAL RESEARCH REVIEWS
- Design of amidobenzimidazole STING receptor agonists with systemic activity
- (2018) Joshi M. Ramanjulu et al. NATURE
- Specific MHC-I Peptides Are Induced Using PROTACs
- (2018) Stephanie M. Jensen et al. Frontiers in Immunology
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Extracellular 5′-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway
- (2017) Jiangang Yu et al. INTERNATIONAL JOURNAL OF CANCER
- Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells
- (2017) Xuan Sun et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
- (2017) Paul A. Beavis et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
- (2017) Jennifer Sheng et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido[2,3-d]pyrimidines and quinazolines
- (2017) Balakumar Chandrasekaran et al. MEDICINAL CHEMISTRY RESEARCH
- A STING-activating nanovaccine for cancer immunotherapy
- (2017) Min Luo et al. Nature Nanotechnology
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival
- (2017) Matthew Gumbleton et al. Science Signaling
- Evolutionary Origins of cGAS-STING Signaling
- (2017) Shally R. Margolis et al. TRENDS IN IMMUNOLOGY
- SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo
- (2017) Zhongqian Hu et al. OncoTargets and Therapy
- Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
- (2017) Junhun Cho et al. Oncotarget
- Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade
- (2017) Jie Bai et al. Oncotarget
- Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival
- (2017) Matthew Gumbleton et al. Science Signaling
- Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity
- (2017) Paulo C. Rodriguez et al. Frontiers in Immunology
- Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
- (2017) Susanne M. Steggerda et al. Journal for ImmunoTherapy of Cancer
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- CD73–adenosine: a next-generation target in immuno-oncology
- (2016) David Allard et al. Immunotherapy
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- (2016) Jorge Garcia Fortanet et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?
- (2016) Pier Andrea Borea et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- CD73 as a novel marker for poor prognosis of oral squamous cell carcinoma
- (2016) ZHEN-HU REN et al. Oncology Letters
- High expression of CD39 in gastric cancer reduces patient outcome following radical resection
- (2016) Xiao-Yan Cai et al. Oncology Letters
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice
- (2016) Wen Liu et al. Oncotarget
- Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity
- (2016) Evelyne Beerling et al. Cell Reports
- Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
- (2016) E. Moore et al. Cancer Immunology Research
- Motolimod effectively drives immune activation in advanced cancer patients
- (2016) Gregory N. Dietsch OncoImmunology
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
- (2015) Marian S. Wettstein et al. DISEASE MARKERS
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells
- (2015) Jing Wang et al. JOURNAL OF IMMUNOLOGY
- α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors
- (2015) Sanjay Bhattarai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
- (2015) Kari R. Fischer et al. NATURE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro
- (2015) RUIMIN WU et al. ONCOLOGY REPORTS
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
- (2015) Juan Fu et al. Science Translational Medicine
- Coordinate Expansion of Murine Hematopoietic and Mesenchymal Stem Cell Compartments by SHIPi
- (2015) R. Brooks et al. STEM CELLS
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Arginase: an old enzyme with new tricks
- (2015) Ruth B. Caldwell et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Anticancer effect of adenosine on gastric cancerviadiverse signaling pathways
- (2015) Ayako Tsuchiya WORLD JOURNAL OF GASTROENTEROLOGY
- Structural insights into the reaction mechanism of S-adenosyl-L-homocysteine hydrolase
- (2015) Yoshio Kusakabe et al. Scientific Reports
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- SHIPi Enhances Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
- (2015) Sandra Fernandes et al. EBioMedicine
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects
- (2015) Taolin Yi et al. Oncotarget
- PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
- (2014) J. Li et al. CANCER RESEARCH
- Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
- (2014) D. Mittal et al. CANCER RESEARCH
- SHP2E76K mutant promotes lung tumorigenesis in transgenic mice
- (2014) Valentina E. Schneeberger et al. CARCINOGENESIS
- Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice
- (2014) M Y Park et al. Mucosal Immunology
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)
- (2014) Wei Qiu et al. BMC STRUCTURAL BIOLOGY
- Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors
- (2014) By Zhao et al. Journal for ImmunoTherapy of Cancer
- Evaluation of molecular model-based discovery of ecto-5′-nucleotidase inhibitors on the basis of X-ray structures
- (2013) Norbert Furtmann et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
- (2013) F. Mussai et al. BLOOD
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
- (2013) Alka Bhatia et al. Expert Review of Clinical Immunology
- Adenosine A2A Receptor as a Drug Discovery Target
- (2013) Manuel de Lera Ruiz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Adenosine—a physiological or pathophysiological agent?
- (2013) Bertil B. Fredholm JOURNAL OF MOLECULAR MEDICINE-JMM
- Role of inositol phospholipid signaling in natural killer cell biology
- (2013) Matthew Gumbleton et al. Frontiers in Immunology
- TGF-β signalling and its role in cancer progression and metastasis
- (2012) Yvette Drabsch et al. CANCER AND METASTASIS REVIEWS
- Small molecule tools for functional interrogation of protein tyrosine phosphatases
- (2012) Rongjun He et al. FEBS Journal
- Modulation of T-cell function by type I interferon
- (2012) David F Tough IMMUNOLOGY AND CELL BIOLOGY
- Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling
- (2012) Anna Dittrich et al. Molecular BioSystems
- Unknown
- (2012) Gwenny Fuhler et al. MOLECULAR MEDICINE
- TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation
- (2012) Nu Zhang et al. NATURE IMMUNOLOGY
- Adenosine and its receptors as therapeutic targets: An overview
- (2012) Sakshi Sachdeva et al. SAUDI PHARMACEUTICAL JOURNAL
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia
- (2011) Dianne Pulte et al. Clinical Lymphoma Myeloma & Leukemia
- Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
- (2011) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Non–lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatasePtpn11(Shp2) on malignant transformation of hematopoietic cells
- (2011) Dan Xu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer
- (2011) Beat M. Künzli et al. Purinergic Signalling
- Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction
- (2011) Dmitri Smirnov et al. VACCINE
- Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112
- (2010) Liwei Chen et al. BIOCHEMICAL PHARMACOLOGY
- Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13
- (2010) S. L. Highfill et al. BLOOD
- Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
- (2010) Melissa A. Geller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Src, Syk, and Tec family kinases: Distinct types of molecular switches
- (2010) J. Michael Bradshaw CELLULAR SIGNALLING
- CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice
- (2010) Xiaofeng Sun et al. GASTROENTEROLOGY
- Intracellular Toll-like Receptors
- (2010) Amanda L. Blasius et al. IMMUNITY
- SHIP1 Inhibition Increases Immunoregulatory Capacity and Triggers Apoptosis of Hematopoietic Cancer Cells
- (2010) R. Brooks et al. JOURNAL OF IMMUNOLOGY
- Development of Potent and Selective Inhibitors ofecto-5′-Nucleotidase Based on an Anthraquinone Scaffold
- (2010) Younis Baqi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
- (2010) Xian Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Toll-like receptors and innate immunity
- (2009) Himanshu Kumar et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2
- (2009) A Suwa et al. BRITISH JOURNAL OF PHARMACOLOGY
- L-Arginine deprivation impairs Leishmania major-specific T-cell responses
- (2009) Markus Munder et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
- (2009) J. M. Wilson et al. JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade
- (2008) Gennady G. Yegutkin BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells
- (2008) X-D Zhou et al. CELL DEATH AND DIFFERENTIATION
- Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds
- (2008) Harshani R. Lawrence et al. JOURNAL OF MEDICINAL CHEMISTRY
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
- (2008) Hiroki Ishikawa et al. NATURE
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors
- (2008) D Miyamoto et al. ONCOGENE
- Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking
- (2008) K. Hellmuth et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Role for SHIP in Stem Cell Biology and Transplantation
- (2008) William Kerr Current Stem Cell Research & Therapy
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started